logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Neuraminidase Inhibitor class drugs

    FiltersReset Filters
    6 results

    • oseltamivir phosphate

      (Oseltamivir phosphate)
      Ajanta Pharma USA Inc.
      Usage: Oseltamivir phosphate for oral suspension is indicated for the treatment of acute, uncomplicated influenza A and B in patients aged 2 weeks and older, symptomatic for up to 48 hours, and for prophylaxis in patients 1 year and older. It's not a substitute for annual vaccination.

    • oseltamivir phosphate

      (Oseltamivir)
      AvKARE
      Usage: Oseltamivir phosphate capsules are indicated for treating acute, uncomplicated influenza A and B in patients aged 2 weeks and older symptomatic for no more than 48 hours, and for prophylaxis in those aged 1 year and older. It is not a substitute for annual influenza vaccination.

    • oseltamivir phosphate

      (Oseltamivir Phosphate)
      AvKARE
      Usage: Oseltamivir phosphate for oral suspension is indicated for treating uncomplicated influenza A and B in patients 2 weeks and older, symptomatic for no more than 48 hours, and for prophylaxis in individuals 1 year and older. It is not a substitute for annual influenza vaccination.

    • oseltamivir phosphate

      (Oseltamivir phosphate)
      MSN LABORATORIES PRIVATE LIMITED
      Usage: Oseltamivir phosphate capsules are indicated for treating acute, uncomplicated influenza A and B in patients aged 2 weeks and older, symptomatic for no more than 48 hours. They are also used for the prophylaxis of influenza in individuals 1 year and older. Annual vaccination is recommended.

    • oseltamivir phosphate

      (OSELTAMIVIR PHOSPHATE)
      Aurobindo Pharma Limited
      Usage: Oseltamivir phosphate oral suspension is indicated for treating acute, uncomplicated influenza A and B in patients 2 weeks and older symptomatic for no more than 48 hours, and for prophylaxis in patients 1 year and older. It is not a substitute for vaccination and may have effectiveness limitations.

    • tamiflu

      (oseltamivir phosphate)
      Genentech, Inc.
      Usage: TAMIFLU is indicated for treating acute, uncomplicated influenza A and B in patients 2 weeks and older within 48 hours of symptom onset, and for prophylaxis in those 1 year and older. It is not a substitute for vaccination and has limitations regarding resistance and specific patient populations.